{"disease":{"id":"endogenous-depression","name":"endogenous depression"},"drugs":{"marketed":[{"drug_id":"nortriptyline-hcl","indication_name":"Endogenous Depression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"nortriptyline HCl","company_name":"Zalicus","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":25,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04160377","title":"A Clinical Trial of Fluvoxamine for Melancholia","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":150,"lead_sponsor_name":"Lingjiang Li","has_results":false}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}